Skip to main content
Clinical Trials/ISRCTN14812004
ISRCTN14812004
Active, not recruiting
未知

The effectiveness and sustainability of health outcomes from an advanced GLP-1-supported digital weight-loss programme in the UK: a randomized controlled trial

Eucalyptus0 sites1,000 target enrollmentMay 27, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Eucalyptus
Enrollment
1000
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 27, 2024
End Date
October 1, 2025
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Eucalyptus

Eligibility Criteria

Inclusion Criteria

  • 1\. Between 18 years and 70 years of age at the time of completing the program’s pre\-questionnaire
  • 2\. Satisfy the Medicines and Healthcare products Regulatory Agency (MHRA) guidelines for tirzepatide (Mounjaro) weight management
  • 3\. BMI of 30kg/m² or more (obesity), or a BMI between 27\-30kg/m² (overweight) and also have weight\-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems

Exclusion Criteria

  • 1\. Outside the 18\-70 year age bracket
  • 2\. Does not have a BMI of 30 kg/m2 or more, or a BMI of 27\-30 kg/m2 with at least one weight\-related comorbidity such as pre\-diabetes, high blood pressure, high cholesterol, heart problems
  • 3\. Has already started tirzepatide treatment as a current subscriber to the Eucalyptus weight\-loss program
  • 4\. Failure to provide baseline measurements within three weeks of receiving confirmation of trial participation

Outcomes

Primary Outcomes

Not specified

Similar Trials